Objectives: Posttransplant Iymphoproliferative disorders (PTLD) can be a significant cause of morbidity in lung transplant (LT) recipients. Risk factors include Epstein-Barr virus (EBV) infection, particularly primary infection, and immunosuppression. This article updates the incidence and presentation of PTLD at our lung transplant program. Methods: We retrospectively reviewed the immunosuppression, EBVserology, and cases of PTLD among 129 lung transplant recipients at risk who survived> I month. Results: There were two cases of PTLD among 129 LT patients, 2/129 (1.6%). One of these patients was among the 6 EBVseroconverters, 1/6 (16.7%), and had a typical presentation of PTLD in the allograft resulting in dissemination and death. The second case of PTLD developed in an EBVseropositive recipient who presented 33 months following LT with isolated colonic involvement. He subsequently died from chronic rejection. Conclusions:The incidence of PTLD in a LT program with a large EBVseropositive population is low, 1.6%. The presentation of PTLD in LT recipients is variable and may present typically with allograft involvement in the first year following transplantation, or late with isolated, extrapulmonic involvement.

Keywords: Lung Transplantation, Epstein-Barr virus, posttransplant Iymphoproliferative disorder